The COPD Pipeline XIV

COPD. 2012 Feb;9(1):81-3. doi: 10.3109/15412555.2012.646587.
No abstract available

MeSH terms

  • Clinical Trials as Topic
  • Drug Combinations
  • Ethanolamines / therapeutic use
  • Extracorporeal Circulation / instrumentation
  • Gene Silencing
  • Humans
  • Isoquinolines / therapeutic use
  • Mometasone Furoate, Formoterol Fumarate Drug Combination
  • Phosphodiesterase Inhibitors / therapeutic use
  • Pregnadienediols / therapeutic use
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pyrimidinones / therapeutic use
  • RNA, Small Interfering / therapeutic use
  • Receptors, CCR2 / antagonists & inhibitors
  • Tobacco Use Cessation Devices

Substances

  • Drug Combinations
  • Ethanolamines
  • Isoquinolines
  • Mometasone Furoate, Formoterol Fumarate Drug Combination
  • Phosphodiesterase Inhibitors
  • Pregnadienediols
  • Pyrimidinones
  • RNA, Small Interfering
  • Receptors, CCR2
  • ensifentrine

Associated data

  • ClinicalTrials.gov/NCT00683722